ArticleInternational journal of clinical and experimental pathology2020
Neuroendocrine carcinoma of the breast with hyperprolactinemia: report of two cases and a minireview.
Article in International journal of clinical and experimental pathology, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
4 citing papers in PubMed, 6 citations in OpenAlex.
- Primary neuroendocrine tumor of the breast: A case report.Oncology letters · 2025Article
- Clinicopathological Characteristics and Prognostic Profiles of Breast Carcinoma with Neuroendocrine Features.Life (Basel, Switzerland) · 2023Article
- Primary neuroendocrine carcinoma of the breast: a rare presentation and review of the literature.Intractable & rare diseases research · 2020Article
- Primary Neuroendocrine Neoplasms of the Breast: Still Open Issues.Frontiers in endocrinology · 2020Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors at 3 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Neuroendocrine carcinoma of the breast (NECB) is a rare type of breast cancer. The clinical features and morphology between NECB and other subtypes of breast cancer are indistinguishable. Currently, the diagnosis of NECB mainly relies on immunohistochemical markers including chromogranin and synaptophysin. It is urgent to find new diagnostic markers for NECB. Some evidence suggests a link between high prolactin level and breast cancer development, however, it is unclear whether NECB may be associated with hyperprolactinemia. Here we report two cases of primary NECB with hyperprolactinemia. One patient had a history of mental disorder, while the other experienced pregnancy. Metastatic and associated tumors were not found in both cases, and postoperative studies showed one case was hormone-receptor-dependent, but the other was hormone-receptor-independent. The cases presented here suggest hyperprolactinemia may contribute to NECB development.
Indexed as
Identifiers
32661484PMC7344007W3043002549What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.